JP2023515845A5 - - Google Patents
Info
- Publication number
- JP2023515845A5 JP2023515845A5 JP2022552310A JP2022552310A JP2023515845A5 JP 2023515845 A5 JP2023515845 A5 JP 2023515845A5 JP 2022552310 A JP2022552310 A JP 2022552310A JP 2022552310 A JP2022552310 A JP 2022552310A JP 2023515845 A5 JP2023515845 A5 JP 2023515845A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- conjugate according
- following formula
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2001974A FR3107648B1 (fr) | 2020-02-27 | 2020-02-27 | conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie |
| FR2001974 | 2020-02-27 | ||
| PCT/FR2021/050332 WO2021170961A1 (fr) | 2020-02-27 | 2021-02-26 | Conjugués anticorps-médicament anti-cd56 et leur utilisation en thérapie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515845A JP2023515845A (ja) | 2023-04-14 |
| JP2023515845A5 true JP2023515845A5 (https=) | 2024-02-22 |
Family
ID=71894885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552310A Pending JP2023515845A (ja) | 2020-02-27 | 2021-02-26 | 抗－ｃｄ５６抗体－薬物複合体およびその治療での使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20230144142A1 (https=) |
| EP (1) | EP4110405A1 (https=) |
| JP (1) | JP2023515845A (https=) |
| CN (1) | CN115515642A (https=) |
| AU (1) | AU2021227413A1 (https=) |
| CA (1) | CA3166699A1 (https=) |
| FR (1) | FR3107648B1 (https=) |
| WO (1) | WO2021170961A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3096259B1 (fr) * | 2019-05-20 | 2023-12-15 | Mc Saf | conjugués anticorps-médicament et leur utilisation en thérapie |
| FR3131835B1 (fr) * | 2022-01-17 | 2025-11-21 | Mc Saf | Procédé de préparation de conjugués anticorps-médicament |
| FR3131836B1 (fr) * | 2022-01-17 | 2025-05-23 | Mc Saf | Conjugués anticorps-médicament pour utilisation thérapeutique |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025149947A1 (en) * | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104640572B (zh) * | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| WO2013177062A2 (en) * | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| FR3008408B1 (fr) * | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| US10548987B2 (en) | 2015-07-31 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-drug conjugates for targeting CD56-positive tumors |
| CN107744592B (zh) * | 2017-09-15 | 2020-04-28 | 四川大学 | 抗cd56抗体与海兔毒素偶联复合物及其制备方法和用途 |
| CN107715119B (zh) * | 2017-09-15 | 2020-11-10 | 四川大学 | 抗cd56抗体与多卡霉素偶联复合物及其制备方法和用途 |
| SG11202006510XA (en) * | 2018-01-08 | 2020-08-28 | Regeneron Pharma | Steroids and antibody-conjugates thereof |
-
2020
- 2020-02-27 FR FR2001974A patent/FR3107648B1/fr active Active
-
2021
- 2021-02-26 JP JP2022552310A patent/JP2023515845A/ja active Pending
- 2021-02-26 CA CA3166699A patent/CA3166699A1/fr active Pending
- 2021-02-26 AU AU2021227413A patent/AU2021227413A1/en active Pending
- 2021-02-26 US US17/802,274 patent/US20230144142A1/en active Pending
- 2021-02-26 WO PCT/FR2021/050332 patent/WO2021170961A1/fr not_active Ceased
- 2021-02-26 CN CN202180017269.9A patent/CN115515642A/zh active Pending
- 2021-02-26 EP EP21714002.9A patent/EP4110405A1/fr active Pending
-
2023
- 2023-06-12 US US18/333,261 patent/US20230405140A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515845A5 (https=) | ||
| Nasiri et al. | Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy | |
| Sau et al. | Advances in antibody–drug conjugates: A new era of targeted cancer therapy | |
| JP2023512036A5 (https=) | ||
| JP7386208B2 (ja) | 抗ｆｏｌｒ１免疫抱合体投薬レジメン | |
| EP3546448B1 (en) | Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof | |
| Yao et al. | A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity | |
| Hamblett et al. | Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate | |
| JP2024522312A (ja) | 抗体薬物複合体の調製方法および使用 | |
| US11801307B2 (en) | Antibody-polymer-drug conjugates | |
| Ogitani et al. | Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology | |
| JP2017514905A5 (https=) | ||
| JP2019535731A5 (https=) | ||
| CN114395050A (zh) | 鹅膏毒素-抗体轭合物 | |
| PE20251072A1 (es) | Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos | |
| KR20240163656A (ko) | 항-canag 항체 컨쥬게이트 | |
| JP2021503915A5 (https=) | ||
| WO2025207828A1 (en) | Nanocomposition comprising modified exatecan and use thereof | |
| Sawant et al. | Understanding the chemistry & pharmacology of antibody–drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives | |
| Kim et al. | Antibody–drug conjugates for targeted anticancer drug delivery | |
| US20240115726A1 (en) | Hydrazone-based saponin derivatives | |
| EP4552655A1 (en) | Antibody-drug conjugates involving erianin and the fabrication methods and applications thereof | |
| JP2019509298A5 (https=) | ||
| Pal et al. | Antibody drug conjugates: a leap ahead in cancer treatment | |
| Yoon | The Development of PSMA-Targeted Drug Conjugates |